Alzheimer's disease

Explore Alzheimer's disease and access the tools you need to better understand this complex condition.

Alzheimer's disease (AD) is the most common form of dementia, affecting approximately 50 million people worldwide as of 2018 – a number expected to reach 152 million in 2050.¹ The neuropathology of AD is characterized by the accumulation of amyloid plaques and neurofibrillary tangles outside and inside neurons respectively. 

Here you can take a deeper look at the disease and its pathophysiology, as well as a better understanding of the antibodies, kits, reagents, and other tools you need for your research.

Overview

• Alzheimer’s disease pathway
• ​Antibodies for AD research
• The role of biomarkers in Alzheimer's disease
• Antibody panels and kits for AD research
• Beta-amyloid and tau
• Key cell and neuronal markers
• References

​​

Alzheimer's disease pathway

​Explore our interactive AD pathway poster to find the best products for your target of interest.

Get the pathway poster

​​​​

Recombinant monoclonal antibodies for Alzheimer's disease research

Get reproducible, batch-to-batch consistency using recombinant monoclonal antibodies for your AD research. These are some of our best selling products. 

Recombinant Anti-Tau antibody [E178] (ab32057)
Recombinant Anti-Tau antibody [EPR22524-95] (ab254256)
Recombinant Anti-beta Amyloid 1-42 antibody [mOC64] - Conformation-Specific (ab201060)
Recombinant Anti-Amyloid Precursor Protein antibody [Y188] (ab32136)
Recombinant Anti-BACE1 antibody [EPR19523] (ab183612)
Recombinant Anti-Apolipoprotein E antibody [EPR19392] (ab183597)
Recombinant Anti-TREM2 antibody [EPR20243] (ab209814)

​

The role of biomarkers in Alzheimer's disease

Learn more about the challenges posed by the blood-brain barrier and the role of biomarkers in AD from Professor Sudha Seshadri, Founding Director of the Glenn Briggs Institute of Alzheimer’s and Neurogenerative Diseases, UT Health San Antonio.

Here Prof. Seshadri highlights the advantages of blood analysis and the importance of biomarkers that can freely cross the blood-brain barrier. Prof. Seshadri talks us through available biomarkers in AD including growth factors (BDNF, NGF, VEGF), markers of microglial inflammation (YKL40) and astrocyte injury (GFAP). She also emphasizes the importance of using classic markers of amyloid and tau. 

​​​​Please find our products to some of the targets mentioned in this video below. 

​

Antibody panels and kits for Alzheimer's disease research

Panels

​Our Alzheimer’s disease panels contain antibodies against several targets in 10 μL sampler vials to give you access to antibodies in a convenient and cost-effective format.

Tau Research (Tau, S198, S199, S202 + T205, S214, S396, S404, S422, T231) Antibody Sampler Panel (ab226492)
​Conformation-Specific Amyloid beta Antibody Sampler Panel (ab218719)
Astrocyte Marker (ALDH1L1, EAAT1, EAAT2, GFAP) Antibody Sampler Panel (ab226481)
Microglia Marker (CD11b, CD45, Iba1, TMEM119) Antibody Sampler Panel (ab226482)​
​Neuroinflammation Marker Antibody Panel - Human (ab263462)
Mature Neuron Marker Antibody Sampler Panel (ab218257)

Kits

Our ELISA kits allow for results which are sensitive and reliable, and are suitable for a wide range of samples, including plasma, cerebrospinal fluid and tissue extract. Our SimpleStep ELISA^® kits can have results within 90-minutes.

Human IL-1a ELISA Kit (ab178008) 
Human TNF alpha ELISA Kit (ab181421)
Cellular ROS/RNS Assay Kit (ab139473)
TUNEL Assay Kit - FITC (ab66108)
Human Amyloid Precursor Protein ELISA Kit (ab216944)
Human Tau ELISA Kit (ab210972)
Human TREM2 ELISA Kit (ab224881)

Beta-amyloid and tau 

Beta-amyloid and tau are two of the biggest players in AD research. To find out more about the role of beta-amyloid and tau in AD progression and to find out more about the products we have available, click the link below.

>>Beta-amyloid and tau tools and reagents

Key cell and neuronal markers 

​To help you get ahead in your Alzheimer’s research, we’ve compiled the best neuronal markers to use in conjunction with our disease-specific antibodies.

References

1. Alzheimer’s Research UK. Dementia Statistics Hub - Global Prevalence. Available at: https://www.dementiastatistics.org/statistics/global-prevalence/.
​​